ADVFN - Advanced Financial Network.
HOME» NYSE » B » BSX Stock Price » BSX Stock News

Boston Scientific Share News

 Boston Scientific Corp. Stock Price
BSX Stock Price
 Boston Scientific Corp. Stock Chart
BSX Stock Chart
 Boston Scientific Corp. Stock News
BSX Stock News
 Boston Scientific Corp. Company Information
BSX Company Information
 Boston Scientific Corp. Stock Trades
BSX Stock Trades

Boston Scientific To Acquire Cameron Health To Build On Heart-Rhythm Business

DOW JONES NEWSWIRES Boston Scientific Corp. (BSX) will acquire privately held company Cameron Health Inc., expanding its key heart-rhythm business. Cameron Health developed the only commercially available subcutaeneous implantable defibrillator, which is an alternative to traditional defibrillators. Boston Scientific will pay $150 million upfront and an additional potential $150 million upon the U.S. Food and Drug Administration's approval of Cameron's S-ICD system. The agreement also calls for up to an additional $1.05 billion in revenue-based milestone payments over a six-year period after FDA approval. The deal is expected to close in the second or third quarter this year. "The acquisition of Cameron Health builds on Boston Scientific's commitment to introducing innovation in the (cardiac rhythm management) space and represents an important part of our strategy to generate top-line revenue and market share growth," said Chief Executive Hank Kucheman. Cameron's S-ICD system sits below the skin and doesn't touch the heart and blood vessels, while conventional implantable defibrillators require thin, insulated wires to pass through the venous system and into the heart. The system has been commercially available in several major European countries since 2009. Cameron received expedited review status and submitted its application to the FDA in December. Boston Scientific anticipates FDA approval in the first half of 2013. Last month, Boston Scientific reported fourth-quarter earnings fell 55% on sales declines in its heart-rhythm and drug-eluting stents businesses as the medical-device maker struggles to grow its revenue amid weakness in key markets. Shares closed at $5.93 Thursday and were unchanged after hours. The stock is up 11% so far this year. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287;

Stock News for Boston Scientific (BSX)
10/08/201506:30:00Boston Scientific Announces Additional Investment And Right To...
10/07/201517:00:00Boston Scientific Launches Online Competition For New Digital...
10/07/201516:30:00Boston Scientific Announces Scheduled Presentations At TCT 2015
10/05/201516:11:28Statement of Changes in Beneficial Ownership (4)
10/05/201516:06:37Current Report Filing (8-k)
10/05/201506:30:00Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable P...
10/02/201516:24:35Statement of Changes in Beneficial Ownership (4)
10/02/201516:24:35Statement of Changes in Beneficial Ownership (4)
10/02/201516:24:35Statement of Changes in Beneficial Ownership (4)
10/02/201516:23:21Statement of Changes in Beneficial Ownership (4)
10/01/201508:30:00Boston Scientific To Webcast Third Quarter 2015 Earnings Call...
09/29/201509:00:00Boston Scientific Launches The Captivator™ EMR Device To Treat D...
09/28/201507:00:00New Survey Reveals True Impact of Severe Asthma on People's Lives
09/28/201506:00:00Eluvia™ Drug-eluting Vascular Stent System Demonstrates 12-month P...
09/22/201508:45:00Technical Data on Healthcare Stocks - Infinity Pharmaceuticals...
09/18/201508:30:00Medical Appliances and Equipment Stocks Technical Report -- Boston...
09/10/201509:00:00Boston Scientific Announces CE Mark for the Vercise™ Primary C...
09/02/201508:30:00Boston Scientific To Participate In 2015 Morgan Stanley Global...
08/26/201508:30:00Boston Scientific To Participate In The 2015 Wells Fargo Healthcare...
08/24/201516:30:00Boston Scientific Announces CE Mark For MRI Compatible Labeling...

Boston Scientific and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations